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Abstract: Delayed gastric emptying (GE) is a frequent non-motor feature in Parkinson´s disease (PD).
This prospective study (clinicaltrials.gov Identifier NCT01518751) investigated GE and visceral percep-
tion in early motor phase PD patients in comparison to age-matched and younger controls. In addition,
the effect of Levodopa on GE was assessed in healthy aged controls. 16 PD patients (Hoehn Yahr 2),
11 sex-/age-matched Ctrl1 and 10 young, male Ctrl2 subjects were subjected to a high caloric (428 kcal)
(13)C-Sodium Octanoate breath test strictly OFF dopaminergic medication. Visceral appetite sensation
was monitored using visual analogue scales (VAS). GE was similarly studied in 7 controls ON/OFF oral
Levodopa. GE was not altered in PD patients compared to age-/sex-matched and younger controls (p =
0.76). Subjective appetite perception was not altered in the PD group in comparison to Ctrl1, but was
significantly higher in Ctrl2 subjects (p = 0.02). 100 mg oral Levodopa/25 mg Benserazide significantly
slowed GE by 18% among healthy controls (p = 0.04). In early motor stage PD OFF dopaminergic
medication, there was no GE slowing after a high caloric test meal. Levodopa, however, caused a robust
GE slowing in healthy aged individuals. Our data indicate that clinically relevant GE slowing in early PD
is related to the iatrogenic effect of dopamine treatment. Subjective appetite perception is not affected
in this disease stage. This data add to the understanding of gastrointestinal symptoms in early motor
stage PD and highlight the influence of dopaminergic medication.
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Abstract Delayed gastric emptying (GE) is a frequent
non-motor feature in Parkinsońs disease (PD). This
prospective study (clinicaltrials.gov Identifier
NCT01518751) investigated GE and visceral perception in
early motor phase PD patients in comparison to age-mat-
ched and younger controls. In addition, the effect of
Levodopa on GE was assessed in healthy aged controls. 16
PD patients (Hoehn & Yahr 2), 11 sex-/age-matched Ctrl1
and 10 young, male Ctrl2 subjects were subjected to a high
caloric (428 kcal) 13C-Sodium Octanoate breath test
strictly OFF dopaminergic medication. Visceral appetite
sensation was monitored using visual analogue scales
(VAS). GE was similarly studied in 7 controls ON/OFF
oral Levodopa. GE was not altered in PD patients com-
pared to age-/sex-matched and younger controls
(p = 0.76). Subjective appetite perception was not altered
in the PD group in comparison to Ctrl1, but was
significantly higher in Ctrl2 subjects (p = 0.02). 100 mg
oral Levodopa/25 mg Benserazide significantly slowed GE
by 18 % among healthy controls (p = 0.04). In early motor
stage PD OFF dopaminergic medication, there was no GE
slowing after a high caloric test meal. Levodopa, however,
caused a robust GE slowing in healthy aged individuals.
Our data indicate that clinically relevant GE slowing in
early PD is related to the iatrogenic effect of dopamine
treatment. Subjective appetite perception is not affected in
this disease stage. This data add to the understanding of
gastrointestinal symptoms in early motor stage PD and
highlight the influence of dopaminergic medication.
Keywords Gastric emptying  Parkinson’s disease  High
caloric test meal  Appetite sensation  Dopaminergic
treatment
Introduction
Due to the increasing recognition of its non-motor features,
Parkinson’s disease (PD) is nowadays recognized as a
systemic alpha-synucleinopathy rather than an isolated
disease of basal ganglia motor control [1]. Symptoms of
autonomic dysfunction are among the most disturbing non-
motor features in PD [2] and their prevalence seems to
increase with advanced disease stages [3]. Several studies
show that gastrointestinal (GI) symptoms account for much
of the autonomic dysfunction disease burden [4, 5].
Delayed gastric emptying (GE) refers to a slowing in
gastric motility in the absence of mechanical obstruction
and has repeatedly been reported in PD patients of different
disease stages [6–12]. However, some studies measured
GE under the influence of dopaminergic medication [6, 7],
some used controls of a different age [6], some used liquid
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or semi-liquid test meals [12], some included patients in
advanced PD disease stages only [10] or assessed GE only
with a low-caloric (240 kcal—calorically equalling one
butter croissant) test meal [7, 8, 11]. The question therefore
remains whether there is altered GE after a medium size
meal in early disease stages in the absence of potentially
interfering medication. We investigated this using a 13C-
Sodium Octanoate breath test (OBT) paradigm strictly OFF
dopaminergic medication using a 428 kcal meal, more
closely representing a standard meal with regards to caloric
and nutritional content.
A considerable number of PD patients display unin-
tended weight loss during the course of their disease and
this can be dramatic in some [13]. It is known that low
initial body weight and weight loss during the course of PD
is associated with increased risk of dyskinesia, malnutrition
and frailty [14], while loss of appetite, constipation and
early satiety have the highest influence on food intake in
malnourished PD patients [15]. We therefore assessed
visceral perception for appetite during ingestion in the
same group of early motor phase PD patients and control
subjects using repetitive visual analogue scales (VAS).
In addition to disease-inherent mechanisms, GI motility
is also subjected to iatrogenic influence in PD: it has been
shown previously using radioscintigraphy experiments that
dopaminergic medication can have a slowing effect on
human gastric emptying [16]. While this technique not only
uses irradiation but is also prone to movement artefacts
[17], we applied a more robust 13C-Sodium OBT paradigm
to replicate and quantify this important iatrogenic effect in
healthy aged controls, as dopaminergic medication remains
the mainstay of treatment for PD.
Methods
This prospective cross-sectional trial (clinicaltrials.gov
Identifier NCT01518751) was approved by the local ethics
committee. Written informed consent was obtained from
all participants prior to participation. Sixteen Hoehn &
Yahr (H&Y) stage 2 idiopathic PD patients (PD) according
to UKPD brain bank criteria, and 11 age- and sex-matched
controls (Ctrl1) were recruited from our movement disor-
ders outpatient clinic and the general population. We did
not keep a screening log. 10 healthy young male controls
(Ctrl2) were included from internal laboratory data
(Table 1). None of the participants were active smokers.
The effect of Levodopa on GE was tested in 7 additional
healthy subjects (Crtrl3). Subjects with medication influ-
encing blood pressure or gastrointestinal motility (includ-
ing anticholinergics, antidepressants, neuroleptics,
laxatives and prokinetic drugs), significant systemic illness
(such as liver/kidney failure, thyroid disease, autoimmune
disorders etc.), hormone replacement therapy, BMI\18 or
[32 kg/m2, symptoms or past medical history of GI dis-
ease or surgery and diabetes mellitus were excluded from
participation.
Patients were on stable dopaminergic treatment prior to
inclusion and stopped dopamine agonists, MAO-B-in-
hibitors and slow-release Levodopa formulations 36 h,
Table 1 Demographic and clinical characteristics of study participants: clinical data of Parkinson disease patients (PD, n = 16), age-and sex-
matched controls (Ctrl1, n = 11) and young male controls (Ctrl2, n = 10); values given in mean ± SD
PD (n = 16) Ctrl1 (n = 11) Ctrl2 (n = 10) Differences between groups
Participant characteristics
Age (years) 66.3 ± 8.5 61.1 ± 7.1 29.7 ± 6.1 \0.001*;\0.001; 0.26#;\0.001 %
Sex (male/female) 10/6 7/4 10/0 v2 = 0.08
BMI (kg/m2) 25.4 ± 3.2 24.1 ± 4.2 24.4 ± 1.3 0.53*
MoCA 25.9 ± 2.1 26.9 ± 2.1 n.a. 0.25
UPDRS III (in OFF state) 28.4 ± 10.4 1.1 ± 1.1 n.a. B0.001
Subjective gastrointestinal symptoms
GCSI 2.5 ± 3.1 1.8 ± 4.5 0.2 ± 0.3 0.22*
LDQ 1.5 ± 1.5 0.9 ± 1.2 1.1 ± 2.0 0.60*
v
2 Chi square-test
BMI body mass index, MoCA Montreal cognitive assessment, UPDRS United Parkinsons Disease Rating Scale, GCSI Gastroparesis Cardinal
Symptom Index, LDQ leeds dysphagia questionnaire
* p values ANOVA test across all three groups

p value Bonferroni post hoc comparison between groups PD vs. Ctrl2
#
p value Bonferroni post hoc comparison between groups PD vs. Ctrl1
%
p value Bonferroni post hoc comparison between groups Ctrl1 vs. Ctrl2

p value Student’s t test comparing PD vs. Ctrl1
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Levodopa and catechol-O-methyltransferase (COMT)-in-
hibitors 12 h before investigations.
GE and visceral perception in PD
The previously described 13C-Sodium OBT [8] consisted
of a solid test meal in the form of two muffins (428 kcal,
12.5 g protein, 18 g fat, 53 g carbohydrates) labelled with
125 mg of 13C-Sodium Octanoate (isotopic purity of
99.1 %, Euriso-Top, Gif-sur-Yvette, France) and 100 ml of
tap water: in short, ingested 13C sodium octanoate is
emptied from the stomach, absorbed in the intestine and
then metabolised to be ultimately exhaled as 13CO2. The
rate limiting step for this is the velocity of gastric emptying
[8, 17]. The 13CO2/
12CO2 isotopic ratio in breath samples
was determined with isotope-selective spectrometry
(Kibion AB, Uppsala, Sweden) and expressed as the
exhaled percentage (of total ingested 13C) dose rate per
hour (PDR in %/h; Fig. 1a). After an overnight fast, all
subjects were tested at 8:00–10:00 AM in the same
examination room at ambient temperature. A VAS for
subjective appetite intensity, nausea, bloating and abdom-
inal pain was to be scored by the subjects in parallel to the
ongoing breath sampling at each time point. VAS data was
analysed by quantification of the area under the curve
(AUC) by the trapezoid method. After a 20 min supine rest
and baseline measurements all subjects ingested the com-
plete test meal. Breath samples and VAS recordings were
collected in 15 min-intervals for 4 h. During testing, sub-
jects remained in a relaxed 40 upright position and
physical activity was restricted. Gastric emptying param-
eters were calculated after performing a non-linear
regression of the PDR curve as described previously [8].
Gastric half emptying time (t50) and the emptying coeffi-
cient (GEC) were calculated from raw data, the latter being
a global index of gastric emptying representing the natural
logarithm of the initial slope of the PDR curve [8, 18].
Effect of levodopa on GE in healthy aged volunteers
In a separate experimental setup, seven aged, healthy, non-
smoking controls (4 males, 48–70 years, no previous
medical history, no regular medication) received a solid
test meal muffin (241 kcal, 14 g proteins, 26 g carbohy-
drates, 9 g fat) labelled with 100 mg 13C-Sodium
Octanoate. After baseline measurements and immediately
before test meal ingestion, subjects received either placebo
or 100 mg levodopa/25 mg benserazide on two separate
days after an overnight fast. Medication/placebo was
administered in a single-blinded manner together with
10 ml of water. All other experimental conditions of the
13C-Sodium OBT paradigm and analysis were performed
as described above.
Statistical analysis
We performed Student‘s t test or one-way ANOVA with
Bonferroni-post hoc analysis for comparison of means, and
Pearson‘s Chi Square test for comparison of nominal data.
Comparison of variance was performed with the Levene
test. Correlation was expressed by Pearson’s coefficient. A
p-level of\0.05 was regarded as significant. Analyses were
performed using GraphPad Prism 6.0 (GraphPad Software
Inc., CA, USA) and IBM(R) SPSS(R) 22 (IBM Corpora-
tion, NY, USA).
Results
Demographics and gastrointestinal symptoms
Participating PD and Ctrl1 subjects did not differ with
regards to sex and age, while male Ctrl2 subjects were
significantly younger (Table 1). PD, Ctrl1 and Ctrl2 sub-
jects were matched for symptoms of dyspepsia and gas-
troparesis by validated standardized questionnaires (Leeds
Dysphagia Questionnaire—LDQ [19], Gastroparesis Car-
dinal Symptom Index—GCSI [20]; one-way ANOVA
p[ 0.05) and body mass index (BMI; one-way ANOVA
p = 0.53; see Table 1). In the cohort studied, on average,
PD patientś age was 66.3 ± 8.5 years at the time of study
and mean disease duration 5.5 ± 4.5 years. Mean Levo-
dopa-equivalent daily dose (LED), calculated from all
dopaminergic medication [21], was 694 ± 340 mg:
patients were treated with dopaminergic medication and a
MAO inhibitor (n = 7), dopamine agonists only (n = 3),
levodopa only (n = 3), or a combination of both. No
patients after deep brain stimulation were included. Mean
UPDRS III in the OFF state was 28.4 ± 10.4. According to
the most prominent motor features upon clinical exami-
nation, disease phenotype was grouped as tremor-dominant
(6/16), akinetic-rigid (7/16) or mixed (3/16).
Gastric emptying and pre-/postprandial visceral
perception
Gastric half emptying time T50 (min) did not differ
between PD (215.18 ± 96.88) and both Ctrl1
(196.16 ± 53.01) and Ctrl2 subjects (216.28 ± 32.81; one-
way ANOVA p = 0.76, see Fig. 1). GEC did not differ
between PD (3.07 ± 0.39), and both Ctrl1 (3.05 ± 0.39)
and Ctrl2 subjects (2.77 ± 0.19; one-way ANOVA
p = 0.09, Fig. 1c, d). T50 also did not differ between
tremor-dominant (206.21 ± 36.95, n = 6), mixed
(167.78 ± 34.75, n = 3) and akinetic-rigid PD subjects
(243.18 ± 140.74, n = 7; one-way ANOVA p = 0.65).
One Ctrl1 (9 %) and 2 akinetic-rigid PD patients (13 %)
1948 J Neurol (2015) 262:1946–1953
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had gastroparesis, defined by t50[ 300 min. Comparison
of variance in between motor phenotype PD patient groups
showed a significantly higher variance in T50 values in the
akinetic-rigid group in comparison to tremor-dominant and
mixed phenotype (Levene test F = 4.27, p = 0.04).
Patients of different motor phenotype did not differ with
regards to LED, LED/kg body weight or number of
dopaminergic medication taken.
Quantification of VAS data for appetite differed signif-
icantly between groups and was higher in Ctrl2
(1031 ± 351) than PD or Ctrl1 subjects (513 ± 447;
496 ± 583; one-way ANOVA p = 0.02; Fig. 1b), while
there was no difference on nausea (21.6 ± 31.2;
18.5 ± 23.7; 3.9 ± 11.3; p = n.s.), bloating (97.9 ±
224.4; 24.3 ± 31.2; 71.5 ± 125.1; p = n.s.), and abdomi-
nal pain (22.2 ± 36.5; 17.5 ± 21.4; 85.5 ± 228.4;
p = n.s.) between groups. GEC/t50 correlated neither with
age, BMI or sex, nor with disease duration, motor
impairment (UPDRS III score) or LED in PD patients.
Influence of Levodopa on gastric emptying
in healthy aged subjects
In comparison to placebo, oral ingestion of 100 mg
Levodopa/25 mg Benserazide caused a significant slowing
of GE in healthy elderly control subjects (t50 (min):
112 ± 15 vs. 132 ± 24 p = 0.04; GEC: 3.67 ± 0.25 vs.
3.34 ± 0.31 p = 0.04; Fig. 1e, f).
Discussion
In this cross-sectional, prospective study using a high
caloric test meal in the strict absence of dopaminergic
medication, there was no overall delayed GE in a
homogenous, representative sample of early motor PD
patients in comparison with healthy, age-matched and
younger controls. Neither PD patient motor impairment as
measured by UPDRS III scores, disease duration nor LED
correlated with GE measures.
Although the comparison of different motor phenotype
showed a higher inter-individual variance in GE and gas-
troparesis (n = 2), only in akinetic-rigid patients, our study
is not powered to imply a role of PD motor phenotype on
GE.
Comparison with previous PD GE studies
These findings contrast with earlier reports of delayed GE
in PD patients [6–12, 18], warranting careful interpretation.
Dopaminergic medication has a marked influence on GE as
shown previously [22] and in this study (Fig. 1e, f). It is
therefore difficult to exclude potential medication bias in
studies that performed GE measurements not in the
dopaminergic OFF condition [6, 7]. The results from study
cohorts not matched for age [6] or consisting of advanced
disease stage PD patients only [10] are difficult to compare
with our results because of substantial methodological
differences. Furthermore, it is has been shown that GE
studied by liquid test meals more often gives abnormal
results [23] and shows a larger variability than solid test
meals [24], rendering PD studies using liquid test meals
difficult to interpret [12].
Previous studies in early motor-stage PD patients that
used a solid test meal off dopaminergic medication found
delayed GE [8, 9, 11]. Patients in the Caucasian cohorts did
not differ from our sample with respect to age, gender
distribution (male preponderance), disease onset, disease
duration and BMI—they received dopaminergic medica-
tion but LED was not calculated [8, 11]. In the Japanese
study, patients were drug-naı̈ve, had a shorter disease
duration, a different gender distribution (female prepon-
derance) and a lower BMI [9]. Identical to our paradigm,
these studies applied a 13C-Sodium Octanoate breath test
after an overnight fast in a similar manner. However, they
used a 240 kcal caloric test meal (calorically corresponding
to one butter croissant), which is only about half the caloric
content of our paradigm. Dopaminergic medication was
stopped 12 h before testing [8, 11] /excluded long-acting
dopaminergic medication [8], whereas in our study, all
medication potentially affecting levodopa metabolism was
stopped 36 h and short-acting dopamine 12 h before test-
ing. In our opinion, there are several aspects that might
explain the rather counterintuitive finding of unchanged
GE in our sample:
Influence of humoral factors on GE
It is known that there is a positive linear correlation
between caloric intake and GE time of solid meals, which
has been demonstrated using the 13C-Sodium Octanoate
breath test and other methods [24–26]. Physiologically, GE
is regulated by both the influence of local vago-vagal
bFig. 1 Quantification of gastric emptying and subjective visceral
perception: data from PD patients (PD), sex- and age-matched (Ctrl1)
and young male controls (Ctrl2) were compared. Gastric emptying
kinetics as 13CO2/
12CO2 isotopic ratio in breath samples were
determined with isotope-selective spectrometry and expressed as the
exhaled percentage (of total ingested 13C) dose rate per hour (PDR in
%/h; a); Mean appetite sensation was measured by visual analogue
scales in parallel to the ongoing breath sampling over 4 h and the area
under the curve quantified by the trapezoid method (b); Gastric
emptying coefficient (GEC; c) and gastric emptying half time (T50;
d) were calculated from gastric emptying raw data. In a separate
experiment gastric emptying in healthy aged controls (n = 7) was
examined after oral placebo or 100 mg Levodopa, resulting in a
significant change in gastric emptying kinetics (e) and t50 (f)
1950 J Neurol (2015) 262:1946–1953
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reflexes and the release of GI hormones [27]. The humoral
response during GE consists of prokinetic (Ghrelin) and
inhibitory factors [glucagon-like peptide 1 (GLP-1), pan-
creatic polypeptide Y (PPY)]. Physiologically, a post-
prandial increase of GLP-I and a significant drop in Ghrelin
prevents an overshoot of GE and fine tunes the release of
nutrients from the stomach into the gut [28]. There is data
to suggest that this humoral response regulating gastric
motility after food intake is altered in early PD patients:
after the administration of a 214 kcal test meal, serum
Ghrelin levels have been found to recuperate less after a
physiological initial drop in PD patients than in controls,
while serum GLP-1 levels were unchanged. This decreased
prokinetic and unchanged inhibitory signaling is in con-
cordance with the observed slowing of GE among PD
patients [29, 30].
We speculate that the caloric content of the test meal
might play a role in explaining the apparent discrepancies
outlined above. The extent of the humoral GI response
depends on the caloric content of the meal [31] and is
regulated, among others, by ileal brake mechanisms [32,
33]. Although we did not measure GI hormone release, we
speculate that the higher caloric content of our test meal
might have triggered a higher Ghrelin response, potentially
influencing GE by a humoral response quantitatively dif-
ferent from the response after a smaller test meal.
We acknowledge the finding of delayed GE in
untreated, early motor stage PD patients after a low
caloric test meal [9, 11]. Nevertheless, a high caloric test
meal more adequately mimics the nutritional intake in the
majority of PD patients with respect to caloric and
nutritional content. Therefore, this paradigm more ade-
quately addresses the question whether there is a disease-
inherent slowing of GE in early motor stage PD. Our
results show that H&Y 2 PD patients overall do not have
clinically relevant delayed GE of a medium sized meal in
the absence of medication.
Influence of the vagal nerve on GE
The autonomic function of the enteric nervous system is
modulated by vagal nerve efferents. Alternatively to an
altered humoral response pattern, GE might be altered by a
changed gastric vagal motor control, as previously sug-
gested [8, 9, 34, 35]. There is histopathological evidence
suggesting a connection between alpha-synuclein
immunoreactive inclusions in the gastric myenteric and
submucosal plexus and the brainstem through the vagal
nerve in PD [36]. However, in contrast to the neurode-
generation caused in central structures in PD, this alpha-
synuclein accumulation does not cause neurodegeneration
in the enteric nervous system, i.e. does not change neuron
numbers [37]. Furthermore, while local vago-vagal reflexes
seem to mainly affect gastric distribution of a meal during
the non-propulsive Lag-phase and sensation of fullness
[27], GE less clearly depends on vagal integrity as it
remains unchanged after vagotomy [38]. Due to the nature
of autonomic function testing, so far a functional impair-
ment of vagal nerve activity in PD patients has not been
proven, although hypothesized.
Our results of unchanged appetite perception indicate
that afferent vagal nerve functioning is not impaired in
early motor PD patients. Physiologically, satiety is induced
by gastric distension and mediated via vagal afferents to
CNS structures [27]. The feeling of satiety is created by
interplay of numerous hormonal and neuronal signals both
on a peripheral and central level, that ultimately contribute
to the regulation of food intake [39]. While it is known that
food intake in PD can be altered on various levels from
afferent metabolic stimuli, sensory perception to mood and
motivation [40], subjective appetite perception relies on
satiety signalling, i.e. vagal afferent functioning. Con-
cluding from our results, this feedback mechanism is not
impaired (sufficiently) to affect appetite perception in
early-motor PD patients.
Influence of dopaminergic medication on GE
The finding of a significant slowing of GE after Levodopa
intake in healthy aged subjects corroborates results of
gamma-scintigraphy experiments [16, 22, 41] and replicates
them for the first time using the 13C-Sodium OBT paradigm.
Interestingly, already our small sample was sufficient to
show a significant 18 % slowing of GE after 100 mg oral
Levodopa—together with the significant slowing in equally
small sample sizes reported by Robertson et al. (n = 8) and
Berkowitz et al. (n = 7), indicating a robust effect of
dopamine on gastric motility [16, 22, 41]. Due to the single
dose paradigm used in our study, we cannot deduct a dose-
dependent slowing effect of dopamine on GE, although
animal data does suggest this [42]. Furthermore, although
an animal study found Ghrelin levels not to be significantly
influenced by intravenous levodopa [43], it is not known in
how far dopaminergic medication per se influences GE
humoral response mechanisms in humans.
The acute effect of levodopa on gastric motility in PD
subjects has not been investigated so far. Our results not
only stress the importance of performing GE examinations
in the strict absence of dopaminergic agents when assess-
ing disease-intrinsic GI motility, but also document a
marked iatrogenic effect of oral dopaminergic therapy.
They do suggest that at least part of the clinically relevant
symptoms of delayed GE in H&Y, 2 PD patients might be
related to treatment rather than disease-inherent effects.
Future studies should address this effect of levodopa on GE
in different disease stages.
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Gastric motility is of central importance to the phar-
macokinetics in PD since Levodopa, still the mainstay of
oral dopaminergic treatment, is absorbed only in the small
intestine [44, 45]. Due to peripheral decarboxylation of
Levodopa to dopamine in the gut mucosa and liver, the
bioavailability of Levodopa with normal GI motility is only
about 30 %—with delayed propagation, absorption and
therefore, more extensive decarboxylation; this number is
reduced even further. It has been shown that Levodopa
pharmacokinetics and gastric emptying kinetics in PD
subjects correlate to a certain extent [46, 47]. From this, it
has been argued that delayed GE causes lower Levodopa
plasma levels impacting on the motor response of medi-
cation [46, 47]. Our data expand this argument and support
the notion that at least in the early-motor phase of the
disease, Levodopa to a great extent might influence its own
absorption due to its slowing effect on GE.
Appetite perception is unchanged in early motor PD
Visceral perception in PD has barely been studied so far,
although unintended weight loss has a high prevalence in
advanced disease stages [13] and is associated with a less
favourable outcome [14]. Our results indicate an age- but
no disease-related effect in appetite perception in early
motor PD and therefore are less likely to account for
unintended weight loss. This is in line with the finding of
decreased appetite sensation with higher age, the so-called
anorexia of aging [48]. For later PD disease stages, sub-
jective appetite perception remains to be studied.
Limitations and conclusion
We are aware of the limitations of this study. Above all, the
relatively small sample size increases the risk for type II
error and warrants a substantiation of the preliminary
results of the sub-group analysis with regards to the
influence of motor phenotype on non-motor symptoms. We
also acknowledge that serial measurements of GI hor-
mones, especially intestinal satiety signals such as chole-
cystokinin, GLP-1, Ghrelin and PPY after test meals of
different caloric size would further substantiate the dis-
cussion of our results. Finally, the effect of levodopa on
gastric motility in different disease stages of PD and its
dose-dependency should be addressed in future studies.
In summary, this study did not find an overall slowing of
GE in early-motor PD using a high caloric test meal.
Delayed GE is an important but neglected iatrogenic side
effect of L-Dopa treatment that needs to be taken into
account in the treatment of individual patients. We con-
clude that clinically relevant GE slowing in early PD is,
however, caused by the iatrogenic effect of dopamine
treatment. Visceral perception for appetite shows an age-
but no disease-related effect in early motor-stage PD,
which indicates largely intact vagal afferent signalling in
this disease stage.
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